ClinicalTrials.gg
Enrolling by invitationNCT06597305Updated Jul 29, 2026

Evaluation of a Twenty-session Cognitive-behavioral Therapy With Anorexia Nervosa (CBT-20-AN) Among Adults (18+)

An interventional study of Twenty Session Cognitive-Behavioral Therapy for Anorexia Nervosa (CBT-20-AN) in Anorexia Nervosa and Atypical Anorexia Nervosa, sponsored by Massachusetts General Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Anorexia Nervosa by Massachusetts General Hospital — 2 open to participants now, 2 under way, none of them phase 3. Anorexia Nervosa · Massachusetts General Hospital.

Planned enrollment
8th of 15
40 · median 40
Started
2024
the only one that year
No phase
3 of 16
2 open now
Registered
15th of 16
by date

Among the 16 studies in Anorexia Nervosa by Massachusetts General Hospital, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is one of 3 with no phase, and was the 15th registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

2 of the 16 studies in Anorexia Nervosa by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Anorexia Nervosa by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The study is a clinical trial assessing the efficacy of a new twenty session cognitive behavioral therapy for adults (18+) with anorexia nervosa (AN) and atypical anorexia nervosa. It is expected that participants will gain a significant amount of weight and experience a significant decrease in eating disorder psychopathology and behavior from pre- to post- treatment and that this will be retained after 6-months.

03

Conditions studied

  • Anorexia Nervosa
  • Atypical Anorexia Nervosa

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Eligible patients must meet criteria for anorexia nervosa. This diagnosis can be conferred via the EDE 17.0D.
  2. Age > 18
  3. Patients must be able to provide and comply with the study procedures.
  4. Patients must be able to complete computer-based self-report questionnaires with adequate accommodation, if necessary.
  5. Patients must have a primary care physician, Adolescent Medicine physician, or consulting physician with eating disorder expertise at Massachusetts General Hospital/Massachusetts General Brigham network who can provide ongoing medical monitoring while the patient takes part in the study.

Exclusion criteria

Exclusion Criteria:

Patients will be excluded if they exhibit:

  1. \< 15, obtained via patient medical chart or from study 2023P000469 or 2018P002915.
  2. HR \<55 or >100, obtained via patient medical chart or from study 2023P000469 or 2018P002915.
  3. Systolic BP (SBP and DBP) \<80 or >160, obtained via patient medical chart or from study 2023P000469 or 2018P002915.
  4. Temperature \< 96.5 F, obtained via patient medical chart or from study 2023P000469 or 2018P002915.
  5. Not eating food by mouth and/or any tube feeding, per EDE
  6. Purging > 4x/week, per EDE.
  7. Active suicidality (suicidal ideation with intent or plan) to the point that more intensive treatment (i.e. acute hospitalization) is required
  8. Active untreated and unstable bipolar disorder (i.e. stable bipolar disorder under care of a psychiatrist is allowed)
  9. Psychosis
  10. Intellectual disability
  11. Any condition that, after the baseline evaluation, is determined to preclude treatment with CBT.
  12. Concurrent psychotherapy. Patients must be willing to take a pause from any ongoing psychotherapy in order to focus on CBT-AN-20, which is in alignment with standard clinical care.
  13. Symptoms that are not appropriate for outpatient level of care and therefore require a higher level of care (i.e. BMI \<15 or purging more than 4x/week)
  14. Homicidal ideation
  15. Inability to speak English well enough to engage in CBT
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    CBT-20-AN

    The single CBT-20-AN arm of this study is experimental, consisting of 20 weekly sessions and one-month, three-month, and six-month follow-ups.

    Behavioral: Twenty Session Cognitive-Behavioral Therapy for Anorexia Nervosa (CBT-20-AN)

Interventions

  • BehavioralTwenty Session Cognitive-Behavioral Therapy for Anorexia Nervosa (CBT-20-AN)

    Twenty session cognitive behavioral therapy for Anorexia Nervosa (CBT-20-AN) is an treatment for Anorexia Nervosa and Atypical Anorexia Nervosa delivered by a mental health clinician. This treatment (CBT-20-AN) lasts just 20 sessions and has been designed to allow individuals with AN to reap the benefits of CBT for eating disorders (up to 40 sessions) in less time, increasing access to care and shortening time to symptom reduction.

06

What researchers measure

Primary outcomes

  1. Patient weight

    Weight collected at each session.

    Time frame: Change from study treatment week one to final session, an average of 25 weeks after week one (measured at weekly study treatment sessions), and to the one, three, and six-month follow-up session, up to 11 months after week one.

  2. Generalized Anxiety Disorder (GAD-7)

    A 7-item scale that measures symptoms of Generalized Anxiety Disorder (GAD), such as feeling anxious or nervous, having trouble relaxing, irritability, and feelings of dread. Scores range from 0 to 21, with higher scores reflecting higher general anxiety.

    Time frame: Change from week one of study treatment to post-treatment following final session, an average of 25 weeks after week one (measured at weeks one, six, and twenty), and to one, three, and six-month follow-up sessions, up to 11 months after week one.

  3. Patient Health Questionnaire - 9 (PHQ-9)

    A 9-item scale that measures symptoms of depression. Scores range from 0 to 27, with higher scores reflecting higher depression.

    Time frame: Change from week one of study treatment to post-treatment following final session, an average of 25 weeks after week one (measured at weeks one, six, and twenty), and to one, three, and six-month follow-up sessions, up to 11 months after week one.

  4. Eating Disorder Examination Interview (EDE)

    A semi-structured interview designed to assess current eating disorder psychopathology.

    Time frame: Change from baseline assessed at screen visit to post-treatment following final session, an average of 25 weeks after baseline assessment.

  5. Eating Disorder Examination Questionnaire (EDE-Q6)

    A 33-item self-report questionnaire that assesses the presence of eating disorders symptoms in the past 28 days. Eating Disorder examination questionnaire (EDE-Q 6.0) Scores range from 0 to 6, with higher scores reflecting higher eating disorder behaviors and attitudes.

    Time frame: Change from week one of study treatment to post-treatment following final session, an average of 25 weeks after week one (measured at weeks one, six, and twenty), and to one, three, and six-month follow-up sessions, up to 11 months after week one.

  6. Eating Disorder - 15 Scale (ED-15)

    A 15-item self-report measure that assesses eating disorder symptoms and behaviors, designed to measure session-by-session change for clinical and research purposes. Scores range from 0 to 6, with higher scores reflecting higher disordered eating attitudes and behaviors.

    Time frame: Change from study treatment week one to post-treatment following final session, an average of 25 weeks after week one (measured at weekly study treatment session), and to the one, three, and six-month follow-up session, up to 11 months after week one.

  7. Working Alliance Inventory Short (WAI-SR)

    A 12-item self-report measure that assess therapeutic alliance between the patient and therapist. (i.e., how comfortable the patient feels with the therapist, how much they trust the therapist, how much they feel the therapist is working towards their desired treatment goals, etc.). Scores range from 5 to 20, with higher scores reflecting higher therapeutic alliance.

    Time frame: Change from week one of study treatment to post-treatment following final session, an average of 25 weeks after week one (measured at weeks one, six, and twenty), and to the six-month follow-up session, up to 11 months after week one.

  8. General Self-Efficacy Measure-Short Form

    A 6-item, short form assessment of the patient's perception of their own general self-efficacy. Scores range from 10 to 40, with higher scores reflecting higher self-efficacy.

    Time frame: Change from week one of study treatment to post-treatment following final session, an average of 25 weeks after week one (measured at weeks one, six, and twenty), and to the six-month follow-up session, up to 11 months after week one.

  9. Approach/Avoidance of Weighing Questionnaire (AAWQ)

    A 9-item, self-report questionnaire that assesses approach and avoidance weighing tendencies. Items 1-3 are summed to provide the approach weighing tendency subscale and items 4-6 are summed to provide the avoidance weighing tendency subscale, with scores ranging from 3-18. Higher scores on each subscale indicate a higher degree of that subscale's weighing tendency.

    Time frame: Change from baseline assessed at screen visit to post-treatment following final session, an average of 25 weeks after baseline assessment.

  10. Three Factor Eating Questionnaire (TFEQ) - Restriction subscale

    An 18-item, self-report questionnaire that assesses the presence and severity of restriction.

    Time frame: Change from baseline assessed at screen visit to session 20 and post-treatment following final session, an average of 20-25 weeks after baseline assessment.

  11. Eating Disorder Inventory-3 (EDI-3) - Drive for Thinness and Body Dissatisfaction subscales

    Subscales from the self-report EDI-3 questionnaire that will be used to assess the presence of both drive for thinness and body dissatisfaction. The drive for thinness subscale is 7 items and body dissatisfaction subscale is 10 items.

    Time frame: Change from baseline assessed at screen visit to session 20 and post-treatment following final session, an average of 20-25 weeks after baseline assessment.

  12. Clinical Impairment Assessment Questionnaire (CIA)

    A 16-item self-report measure of the severity of psychosocial impairment due to eating disorder features.

    Time frame: Change from week one of study treatment to post-treatment following final session, an average of 25 weeks after week one (measured at weeks one, six, and twenty), and to one, three, and six-month follow-up sessions, up to 11 months after week one.

  13. Quality of life questions

    A set of two qualitative questions, developed by the study team, which assess improvements in quality of life since starting treatment ("How has your life improved since beginning treatment?") and areas still needing improvement ("What areas of your life could still be improved?").

    Time frame: Change from week six of study treatment to post-treatment following final session, an average of 25 weeks after week one (measured at weeks one, six, and twenty), and to one, three, and six-month follow-up sessions, up to 11 months after week one.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for May 2029, 61 months after the start.

Of 149 non-industry interventional studies with no phase under Anorexia Nervosa, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 61 months is above that.

Counting every sponsor, half of 149 studies reached it within 43 months; a quarter within 24 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2024
First posted
Sep 19, 2024
StartActual
Apr 22, 2024
Primary completionEst.
May 31, 2029
CompletionEst.
May 31, 2029
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06597305
Responsible party
Kendra R. Becker, Ph.D. (Eating Disorder Clinical and Research Program (EDCRP) Director of Translational Research/Associate Professor of Psychiatry, Massachusetts General Hospital) — Principal investigator
First posted
Sep 19, 2024
Start date
Apr 22, 2024
Primary completion
May 31, 2029 (estimated)
Completion
May 31, 2029 (estimated)
Last update
Jul 29, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion